Hear an expert overview of emerging options for prevention and outpatient treatment of COVID-19, and learn the rationale for increased federal investment into developing oral antivirals against SARS-CoV-2.
Review compelling new data on the use of monoclonal antibodies as postexposure prophylaxis for persons exposed to SARS-Cov-2 and as outpatient therapy and inpatient therapy for persons with COVID-19.
Join Arthur Kim, MD, as he discusses exciting data supporting the implementation of oral and IV antiviral medications for postexposure prophylaxis and treatment of SARS-CoV-2.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.